Thank you very much for the invitation and for the opportunity to speak with the committee today.
My name is Dr. Pouya Azar. I am a clinician scientist specializing in addiction psychiatry and pain medicine, so I divide my time between clinical care and research. Clinically, I work in the emergency department, where I care for people presenting with pain and addiction-related concerns. The other half of my time is devoted to research through my professorship at the University of British Columbia. My program focuses on developing practical clinical tools to address the drug poisoning crisis, particularly the challenges created by fentanyl.
As a society, we look at the overdose crisis, at the lives lost and the harms visible on the streets in so many Canadian cities, and we have trouble seeing a way out.
I'm here to provide a message of hope. My career has given me a perspective shaped by two very different periods in addiction medicine. I practised during the heroin era, before fentanyl became widespread, and I have seen first-hand how fentanyl changed clinical practice and contributed to a public health emergency. Fentanyl is a very different drug from heroin and prescription opioids. It is far more potent than morphine, and its effects on the body differ in important ways from those of heroin.
As fentanyl became more prevalent, the treatment approaches and protocols we had relied on became less effective for many patients. The evidence we had was increasingly difficult to apply. In practice, we found ourselves facing an evidence gap at a time when more and more people were dying from drug poisoning. That clinical need led me to build a research program focused on developing and evaluating treatment protocols specifically for people who use fentanyl.
Our approach is grounded in pharmacology and evidence. We need treatments that reflect the realities of fentanyl use and the needs of patients in front of us. Unfortunately, that approach is not yet consistently reflected in the clinical practice across North America. Current guidelines have not kept pace with the changes in the drug supply or with what we are seeing in patients. We need to update our treatments and strengthen the evidence behind them.
We cannot expect better outcomes if we continue relying on approaches that are not working well for the people we are trying to treat. We have seen the consequences of policy and practice that do not adequately account for evidence. In British Columbia, the prescription of pharmaceutical opioids through the safer supply program was intended to reduce people's exposure to the illicit drug supply.
My colleagues and I raised concerns that this approach was not sufficiently supported by pharmacology, or by the broader evidence on opioid exposure and opioid-related harms. In our clinical work, we also saw concerns about diversion, including prescription opioids reaching people who were not the intended recipients. This included children and adolescents developing opioid addiction. The provincial government ultimately ended the unwitnessed component of this program.
Now, please allow me to be clear. Medication is only a first step. Addiction is a biopsychosocial condition. Medication can be essential, but it cannot address addiction on its own. Effective care must also respond to the social and environmental conditions people face, as well as co-occurring mental health concerns. If we want treatment to work, we need to support people with the full range of care and services that recovery requires.
Now, I do want to close with a message of hope. Opioid use disorder is treatable: Recovery is possible. We have developed more effective treatment approaches designed for people who use fentanyl, and continued research can help us improve them. Funding is urgently needed to continue developing, evaluating and implementing these treatment approaches to support recovery and save lives. An evidence-based approach gives us a real opportunity to reduce harm and help people who enter and remain in treatment.
Thank you. I'm happy to take questions.
